Search Results

The Sabin Vaccine Institute yesterday presented the Albert B. Sabin Gold Medal to physician-researchers Keith Paul Klugman and Shabir Ahmed Madhi, and its Rising Star award to infectious diseases epidemiologist Nicole Elaine Basta at a ceremony in the National Academy of Sciences building in Washington D.C.

The Sabin Vaccine Institute has launched a Phase 2 clinical trial for its vaccine candidate against the lethal Marburg virus.

STAAR Surgical Company, a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses for myopia, astigmatism and presbyopia, announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel.

The Sabin Vaccine Institute today announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded Sabin a multi-year contract with funding potential for up to $214 million to advance the development and production of single-dose vaccine candidates for Ebola Sudan and Marburg virus diseases.

The Sabin Vaccine Institute honored two extraordinary scientists for their breakthrough vaccine research that changed the course of the COVID-19 pandemic, advanced public health, and saved countless lives.

EverGlade Consulting (“EverGlade”), a national consulting firm, has helped Sabin Vaccine Institute successfully secure up to $214 million in funding through a contract with the Biomedical Advanced Research and Development Authority (“BARDA”) to advance the development and production of single-dose vaccine candidates for Ebola Sudan and Marburg virus diseases.

PharmaJet® announced that their poster will be presented on March 1-3, 2022 at the Vaccination Acceptance Research Network conference, sponsored by the Sabin Vaccine Institute.